Evidence map›Paper›PMID 31275541›Full record

ArticleJournal of thyroid research2019

Performance of the American Thyroid Association Risk Classification in a Single Center Cohort of Pediatric Patients with Differentiated Thyroid Cancer: A Retrospective Study.

Raad Alwithenani, Sarah DeBrabandere, Irina Rachinsky, S Danielle MacNeil, Mahmoud Badreddine, Stan Van Uum

Registry-linked trialAbstract read
In one paragraph

Article in Journal of thyroid research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05658809 (Total Thyroidectomy Versus Hemithyroidectomy for Patients With Single Thyroid Nodule , Prospective Comparative Study), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05658809 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Total Thyroidectomy Versus Hemithyroidectomy for Patients With Single Thyroid Nodule , Prospective Comparative Study

TypeinterventionalSponsorAssiut UniversityRan2022 to 2023Enrolled40ConditionsThyroid NoduleArmsthyroidectomy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raad AlwithenaniDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Sarah DeBrabandereDepartment of Diagnostic Imaging, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Irina RachinskyDepartment of Diagnostic Imaging, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
S Danielle MacNeilDepartment of Otolaryngology-Head and Neck Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.ORCID 0000-0001-6666-9055
Mahmoud BadreddineDepartment of Diagnostic Imaging, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Stan Van UumDepartment of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.ORCID 0000-0002-0150-8223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferentiated thyroid cancer (DTC) is the most common endocrine malignancy in children. Retrospective studies show conflicting results regarding predictors of persistent and recurrent disease after initial therapy. In 2015, the American Thyroid Association (ATA) proposed a clinical classification system to identify pediatric thyroid cancer patients at risk for persistent/recurrent disease. MATERIAL AND

methodsWe retrospectively included all patients in our registry diagnosed with papillary DTC at ≤ 18 years of age. We analyzed the prognostic performance of the ATA classification and other risk factors for predicting response to initial treatment and final outcome in pediatric DTC.

resultsWe included 41 patients, 34 females and 7 males, diagnosed with papillary DTC at a mean (SD) age of 16.2 (1.8) years. Based on the ATA pediatric risk classification, patients were categorized as low (61%), intermediate (10%), or high risk (29%). The median follow-up period was 7.3 (1-41) years. After initial treatment, disease free status was achieved in 92%, 50%, and 42% of the low, intermediate, and high risk groups, respectively (P <0.01). At the last visit, persistent disease was present in 12%, 25%, and 33% (P=0.27). Assessing other risk factors, only the presence of distant metastases at diagnosis resulted in increased presence of persistent disease at last follow-up (P=0.03).

conclusionThis study supports the clinical relevance of the ATA risk classification for predicting the response to initial treatment. There was no clear prediction of long-term outcome, but this may be due to limited power caused by the small number of patients.

Identifiers

PMID31275541
PMCPMC6582784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.